GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZS Pharma Inc (FRA:0ZS) » Definitions » EBIT per Share

ZS Pharma (FRA:0ZS) EBIT per Share : €-4.13 (TTM As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is ZS Pharma EBIT per Share?

ZS Pharma's EBIT per Share for the three months ended in Sep. 2015 was €-1.24. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2015 was €-4.13.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for ZS Pharma's EBIT per Share or its related term are showing as below:

FRA:0ZS's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

ZS Pharma's EBIT for the three months ended in Sep. 2015 was €-31.25 Mil.

ZS Pharma EBIT per Share Historical Data

The historical data trend for ZS Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZS Pharma EBIT per Share Chart

ZS Pharma Annual Data
Trend Dec12 Dec13 Dec14
EBIT per Share
- -2.37 -4.38

ZS Pharma Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.62 -0.78 -0.95 -1.15 -1.24

ZS Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

ZS Pharma's EBIT per Share for the fiscal year that ended in Dec. 2014 is calculated as

EBIT per Share(A: Dec. 2014 )
=EBIT/Shares Outstanding (Diluted Average)
=-51.51/11.768
=-4.38

ZS Pharma's EBIT per Share for the quarter that ended in Sep. 2015 is calculated as

EBIT per Share(Q: Sep. 2015 )
=EBIT/Shares Outstanding (Diluted Average)
=-31.254/25.154
=-1.24

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZS Pharma  (FRA:0ZS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

ZS Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of ZS Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ZS Pharma (FRA:0ZS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZS Pharma Inc (FRA:0ZS) » Definitions » EBIT per Share
Comparable Companies
BOM:500488 SGX:H02 SZSE:002424 SZSE:002099 DHA:SQURPHARMA SZSE:300267 SZSE:300357 NSE:PFIZER XKRX:000100 SZSE:002118 SZSE:002019 BOM:500674 XKRX:069620 HKSE:00512 TSE:4534 AERI SHSE:600664 SZSE:002262 XKRX:068760 HKSE:01666
Traded in Other Exchanges
N/A
Address
Website
http://www.zspharma.com
ZS Pharma Inc was incorporated in Delaware in February 2008. The Company is a biopharmaceutical company engaged in the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It was initially engaged in the development of ZS-9, its product candidate in Phase 3 development for the treatment of hyperkalemia. Hyperkalemia is characterized by elevated levels of potassium in the blood (greater than 5.0 mEq/L) and is a life-threatening condition that occurs frequently in patients with chronic kidney disease (CKD), heart failure, and diabetes. ZS-9 is currently in Phase 3 clinical development. ZS-9 is a therapy to treat hyperkalemia, regardless of the underlying cause, and allows patients to benefit from the cardio-renal protective effect of RAAS therapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that address CKD, HF and metabolic diseases. It faces competition from many pharmaceutical and biotechnology companies that are researching and selling products to treat CKD, HF and metabolic diseases. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

ZS Pharma (FRA:0ZS) Headlines

No Headlines